Dow Jones
32.030,11 -530,49 (-1,63%) Nasdaq
11.669,96 -190,14 (-1,60%) Nikkei 225
27.419,61 -47,00 (-0,17%) EUR/USD
1,0910 +0,0045 (+0,4146%) BTC-EUR
25.396,80 -392,53 (-1,52%) CMC Crypto 200
603,31 -12,63 (-2,05%)
BYD Jan 2024 65.000 call
| Chiusura precedente | 7,20 |
| Aperto | 18,30 |
| Denaro | 8,10 |
| Lettera | 8,50 |
| Prezzo d'esercizio | 65,00 |
| Scadenza | 2024-01-19 |
| Min-Max giorno | 7,20 - 7,20 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 768 |
- GlobeNewswire
Gaming and Leisure Properties, Inc. Reports Record Fourth Quarter Results, Establishes 2023 Guidance and Announces 2023 First Quarter Dividend of $0.72 per Share and Special Dividend of $0.25 per Share
WYOMISSING, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) (“GLPI” or the “Company”) today announced record results for the fourth quarter and year-ended December 31, 2022. Financial Highlights Three Months Ended December 31,Year Ended December 31, (in millions, except per share data) 2022 Actual 2021 Actual2022 Actual 2021 Actual Total Revenue $336.4 $298.3$1,311.7 $1,216.4 Income From Operations $275.5 $204.4$1,029.9 $841.8 Net income $199.6 $119.6$70
- GlobeNewswire
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candida
